Targeting interleukin-1 beta (IL-1β) with a drug reduced major adverse cardiovascular events (MACE) by approximately 15% in a susceptible population.

Every Sunday: the week’s new conflicts and verdict changes — and nothing else.

Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.